Clinical and preclinical characterization of CD99 isoforms in acute myeloid leukemia.
In an effort to identify target genes in acute myeloid leukemia, we compared gene expression profiles between normal and acute myeloid leukemia cells from various publicly available datasets. We identified CD99, a gene that is upregulated in patients with acute myeloid leukemia. In 186 patients from The Cancer Genome Atlas - acute myeloid leukemia dataset, CD99 was overexpressed in patients with FLT3-ITD and was downregulated in patients with TP53 mutations. CD99 is a transmembrane protein expressed on leukocytes and plays a role in cell adhesion, trans-endothelial migration and T cells differentiation. CD99 gene encodes two isoforms with distinct expression and functional profiles in both normal and malignant tissues. Here, we report that though the CD99 long isoform initially induces an increase in cell proliferation, it also induces higher levels of reactive oxygen species (ROS), DNA damage, apoptosis and subsequent decrease in cell viability. In several leukemia murine models, the CD99 long isoform delayed disease progression and resulted in lower leukemia engraftment in the bone marrow. Furthermore, the CD99 monoclonal antibody reduced cell viability, colony formation, cell migration as well as induced cell differentiation and apoptosis in leukemia cell lines and primary blasts. Mechanistically, CD99 long isoform resulted in transient induction followed by a dramatic decrease of both ERK and SRC phosphorylation. Altogether, our study provides new insights into the role of CD99 isoforms in acute myeloid leukemia that could potentially be relevant for the preclinical development of CD99 targeted therapy.